CVS Q2 Deep Dive: Pharmacy Strength and Aetna Recovery Drive Guidance Boost

Diversified healthcare company CVS Health (NYSE:CVS) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 8.4% year on year to $98.92 billion. Its non-GAAP profit of $1.81 per share was 23.9% above analysts’ consensus estimates.

Is now the time to buy CVS? Find out in our full research report (it’s free).

StockStory’s Take

CVS Health’s second quarter results surpassed Wall Street’s expectations, with management attributing the outperformance primarily to operational improvements in its Aetna business and continued momentum in pharmacy operations. CEO J. David Joyner highlighted technology-driven process enhancements at Aetna and a focus on customer experience across pharmacy and consumer wellness as key contributors. The company also benefited from market disruption caused by competitor pharmacy closures and successful integration of new prescription volume, which drove higher same-store sales. CFO Brian Newman noted that, despite ongoing reimbursement pressures in retail pharmacy, strategic investments and execution allowed CVS to deliver a solid quarter.

Looking forward, CVS Health’s raised full-year guidance is underpinned by confidence in ongoing Aetna margin recovery, further deployment of cost-based pharmacy reimbursement models, and disciplined cost management. Management emphasized a cautious approach to medical cost trends, particularly in Medicare and value-based care delivery, while continuing to expand technology and operational improvements. CEO Joyner stated, “We will maintain this intense focus, continuing to diligently execute against our margin recovery plan,” and reiterated the importance of innovation in pharmacy benefits management and a transition to more predictable, transparent reimbursement structures as drivers for sustainable growth.

Key Insights from Management’s Remarks

Management highlighted progress in Aetna’s operational turnaround, pharmacy strategy, and innovation in care delivery as the main sources of upside in the quarter.

• Aetna margin recovery: Leadership credited operational improvements and technology adoption within Aetna for driving better member experiences and offsetting elevated medical costs. The business benefited from improved risk adjustment, disciplined pricing, and a focus on higher-margin Medicare products.
• Pharmacy disruption benefits: The closure of competitor pharmacies and the integration of acquired prescription files contributed to increased prescription volume and retail share gains. Management noted this momentum as a result of proactive technology investments and service enhancements.
• PBM (pharmacy benefit manager) innovation: CVS’s Caremark PBM business continued to adapt to rising drug costs by introducing competition among drug manufacturers, particularly in the GLP-1 weight loss category, and launching comprehensive weight management programs that combine medication with clinical support.
• Value-based care pressures: The Oak Street Health segment experienced higher-than-expected medical costs due to a more complex patient mix and robust benefit offerings. While Signify Health offset some of this pressure, management is focused on operational improvements and leadership changes to address cost trends in value-based care.
• Front store retail strategy: Efforts to grow the front-of-store business showed early signs of success, with management emphasizing marketing, vendor collaboration, and leveraging pharmacy traffic to increase retail share in a traditionally challenged segment.

Drivers of Future Performance

Management’s outlook for the year centers on continued Aetna recovery, pharmacy model transitions, and disciplined cost management amid persistent healthcare cost pressures.

• Ongoing Aetna improvement: The company expects further margin recovery from Aetna, especially as half of its Group Medicare Advantage contracts come up for renewal in 2026. Management is cautiously optimistic about sustaining Medicare and Medicaid performance through targeted product and pricing strategies.
• Cost-based pharmacy model rollout: CVS plans to expand its cost-based pharmacy reimbursement model—CostVantage—into its government business, aiming for more predictable and sustainable margins in the coming years. Management believes this transition will help offset historical reimbursement erosion.
• Managing healthcare delivery costs: Persistent elevated costs in value-based care, especially at Oak Street Health, remain a headwind. Leadership is investing in technology, talent, and operational changes to improve medical cost management and expects gradual improvement, but acknowledges that some contracts may take multiple cycles to reach target profitability.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be focused on (1) signs of continued margin recovery and operational improvement in Aetna, (2) measurable progress in expanding the cost-based pharmacy model to government segments, and (3) stabilization of medical cost trends in value-based care delivery. Developments in pharmacy benefit management innovation and the pace of front store retail recovery will also be important signals for assessing CVS Health’s execution against its strategy.

CVS Health currently trades at $65.50, up from $62.32 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.